StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Acquired R&D Technology Rights by Quarter

Acquired R&D Technology Rights — Net Carrying Value ($M) ($M)

QuarterlyAnnual

Amgen Acquired R&D Technology Rights: $105M in Q2 2026, down 19.8% from a year earlier. That is the lowest of the 37 quarters on record here.

Latest, Q2 2026
105
Period ended Jun 30, 2026
Change on a year earlier
-19.8%
131 in Q2 2025
History
37 quarters
Since Q4 2015
Sources
34
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-05) ↗

Reported in Form 10-Q / 10-K Goodwill and Other Intangible Assets Note (XBRL).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAcquired R&D Technology Rights — Net Carrying Value ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026105-19.8%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 2026112-15.8%Form 10-Q (filed 2026-05-01) ↗
Q4 2025Dec 31, 2025120-13.7%Form 10-Q (filed 2026-08-05) ↗
Q3 2025Sep 30, 2025125-15.0%Form 10-Q (filed 2025-11-05) ↗
Q2 2025Jun 30, 2025131-13.8%Form 10-Q (filed 2025-08-06) ↗
Q1 2025Mar 31, 2025133-16.4%Form 10-Q (filed 2025-05-02) ↗
Q4 2024Dec 31, 2024139-16.3%Form 10-K (filed 2026-02-13) ↗
Q3 2024Sep 30, 2024147-12.5%Form 10-Q (filed 2024-10-31) ↗
Q2 2024Jun 30, 2024152-14.6%Form 10-Q (filed 2024-08-07) ↗
Q1 2024Mar 31, 2024159-13.1%Form 10-Q (filed 2024-05-03) ↗
Q4 2023Dec 31, 2023166-11.7%Form 10-K (filed 2025-02-14) ↗
Q3 2023Sep 30, 2023168-12.5%Form 10-Q (filed 2023-10-31) ↗
Q2 2023Jun 30, 2023178-18.3%Form 10-Q (filed 2023-08-04) ↗
Q1 2023Mar 31, 2023183-23.8%Form 10-Q (filed 2023-04-28) ↗
Q4 2022Dec 31, 2022188-23.0%Form 10-K (filed 2024-02-14) ↗
Q3 2022Sep 30, 2022192+7.9%Form 10-Q (filed 2022-11-04) ↗

Breakdown

What makes up acquired R&D Technology Rights

Cite this data

StockData. (2026). Amgen Acquired R&D Technology Rights ($M), quarterly Q4 2015–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/fl-rdtech-net

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.